The stock of Mediwound Ltd (NASDAQ:MDWD) hit a new 52-week low and has $4.64 target or 14.00% below today’s $5.40 share price. The 9 months bearish chart indicates high risk for the $116.98 million company. The 1-year low was reported on Nov, 14 by Barchart.com. If the $4.64 price target is reached, the company will be worth $16.38M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 27,077 shares traded hands or 34.20% up from the average. Mediwound Ltd (NASDAQ:MDWD) has declined 27.04% since April 12, 2016 and is downtrending. It has underperformed by 32.03% the S&P500.
Mediwound Ltd (NASDAQ:MDWD) Ratings Coverage
Out of 4 analysts covering MediWound (NASDAQ:MDWD), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. MediWound has been the topic of 4 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The company was initiated on Wednesday, March 23 by SunTrust. Wells Fargo initiated Mediwound Ltd (NASDAQ:MDWD) on Wednesday, August 17 with “Outperform” rating. Credit Suisse reinitiated Mediwound Ltd (NASDAQ:MDWD) rating on Monday, August 10. Credit Suisse has “Outperform” rating and $14 price target.
According to Zacks Investment Research, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel.”
Another recent and important Mediwound Ltd (NASDAQ:MDWD) news was published by Marketwatch.com which published an article titled: “Virtual Stock Exchange” on March 21, 2014.
MDWD Company Profile
MediWound Ltd., Incorporated on January 27, 2000, is a biopharmaceutical firm focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company’s proteolytic enzyme technology. It offers NexoBrid in Europe and Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.